AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump

Core Insights - AstraZeneca has initiated the construction of a new plant in Virginia, committing to an investment of $4.5 billion to enhance domestic drug production in response to governmental calls for increased U.S. manufacturing and reduced costs [1] Company Summary - The new facility represents AstraZeneca's strategic move to align with President Donald Trump's initiative for more medicines to be produced within the United States [1]